Recurrent audiovestibular dysfunction and associated neurological immune‐related adverse events in a melanoma patient treated with nivolumab and ipilimumab-Reference-Cited by-同舟云学术

Recurrent audiovestibular dysfunction and associated neurological immune‐related adverse events in a melanoma patient treated with nivolumab and ipilimumab

Published:2020-09-05 Issue:11 Volume:42 Page:
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Choi Jonathan S.¹^ORCID,Chen Merry²,McQuade Jennifer L.³,Appelbaum Eric¹,Gidley Paul W.¹,Nader Marc‐Elie¹^ORCID

Affiliation:

1. Department of Head and Neck Surgery The University of Texas MD Anderson Cancer Center Houston Texas USA

2. Department of Neuro‐Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

3. Department of Melanoma Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.26455

Reference21 articles.

2. Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies

3. Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

5. Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Monoclonal Antibody Usage on Hearing Outcomes: A Systematic Review;The Laryngoscope;2024-09-13

2. Clinical Patterns and Factors Contributing to Ophthalmic and Otologic Events Associated With Immune Checkpoint Inhibitors: A Narrative Review;Cureus;2024-08-10

3. Ototoxicity in Immune Checkpoint Inhibitors Therapy;Otolaryngologia Polska;2024-06-30

4. Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response;Cancers;2023-10-27

5. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data;Supportive Care in Cancer;2023-10-11